Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2019-09-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
关于公司药品通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a pharmaceutical product passing a regulatory consistency evaluation by the National Medical Products Administration (国家药品监督管理局). It details the drug's approval, basic information, sales data, and potential impact on the company. The document is short (1110 characters) and serves as a formal public disclosure of regulatory approval and business impact rather than a full financial report or detailed management discussion. It does not contain financial statements or detailed financial analysis, nor is it a report publication announcement or certification. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2019-09-29 Chinese
关于股东股权解除质押暨再质押的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (823 characters) regarding the release and re-pledging of shares by a major shareholder (China Baoan Group) of the company. It details the number of shares released from pledge and re-pledged, the shareholder's total holdings, and the pledge ratios. There is no financial statement, no detailed report, no meeting materials, no voting results, no legal proceedings, no executive changes, and no earnings data. The content is about share pledge status, which relates to capital structure but is specifically about share pledging by a major shareholder. This fits best under a regulatory announcement category related to shareholding or capital changes. However, it is not a new share issue or capital change (SHA), nor a major shareholding notification (MRQ) since it does not report a change in ownership percentage but rather a pledge status change. The closest fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. Therefore, the document is classified as Regulatory Filings (RNS) with high confidence.
2019-09-23 Chinese
2019年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a '2019 年半年度报告摘要' which translates to '2019 Semi-Annual Report Summary'. It contains detailed financial data for the first half of 2019, including assets, net profit, earnings per share, and changes in accounting policies. It also includes management discussion and analysis of business operations and financial performance for the half-year period. The document explicitly states it is a summary of the half-year report and references the full half-year report published on official stock exchange and regulatory websites. The length is 4477 characters, which is sufficient to contain substantive financial data and analysis, not just an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2019
2019-08-23 Chinese
2019年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2019 年半年度报告' which translates to '2019 Semi-Annual Report'. It contains detailed financial data, including income, profit, cash flow, assets, liabilities, and business analysis for the period January 1, 2019 to June 30, 2019. The document is comprehensive, with over 15,000 characters, and includes sections such as company overview, financial indicators, business summary, management discussion and analysis, and financial statements. It explicitly states it is a half-year report and includes unaudited financial data. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2019
2019-08-23 Chinese
第十届董事会第二次会议决议公告
Report Publication Announcement Classification · 95% confidence The document is a board meeting resolution announcement from Mayinglong Pharmaceutical Group Co., Ltd. It details the approval of an accounting policy change and the approval of the 2019 semi-annual report and its summary. However, the document itself does not contain the full semi-annual report or detailed financial statements; instead, it references that the full report and summary were published separately on August 24, 2019, in newspapers and on the Shanghai Stock Exchange website. The document length is short (877 characters) and serves as an announcement of the board's resolutions rather than the report itself. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than the actual Interim/Quarterly Report (IR).
2019-08-23 Chinese
第十届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board of Mayinglong Pharmaceutical Group Co., Ltd. It discusses the approval of an accounting policy change and the approval of the 2019 semi-annual report and its summary. The document is short (1039 characters) and primarily announces the supervisory board's approval and opinions on the half-year report rather than containing the full financial statements or detailed financial data itself. It also references the full 2019 semi-annual report published elsewhere. Therefore, this document is an announcement related to the interim report rather than the report itself. According to the rules, such announcements are best classified as Regulatory Filings (RNS) because it does not contain substantive financial data or the full report but is an official announcement about the report and related approvals.
2019-08-23 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.